INTRA-CELLULAR THERAPIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.26 USD | +1.57% |
|
+1.23% | +2.29% |
| Sales 2024 * | 662M 52.96B | Sales 2025 * | 923M 73.86B | Capitalization | 7.72B 618B |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -4.72B | Net income 2025 * | 108M 8.65B | EV / Sales 2024 * | 10.5 x |
| Net cash position 2024 * | 755M 60.43B | Net cash position 2025 * | 839M 67.2B | EV / Sales 2025 * | 7.46 x |
| P/E ratio 2024 * |
-117
x | P/E ratio 2025 * |
64.6
x | Employees | 610 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Intra-Cellular Therapies, Inc.
More recommendations
More press releases
| 1 day | +1.57% | ||
| 1 week | +1.23% | ||
| Current month | +5.87% | ||
| 1 month | +8.81% | ||
| 3 months | +8.74% | ||
| 6 months | +52.50% | ||
| Current year | +2.29% |
1 week
71.35
76.89
1 month
64.1684.89
Current year
62.7884.89
1 year
45.5084.89
3 years
28.4084.89
5 years
6.7584.89
10 years
6.7584.89
| Managers | Title | Age | Since |
|---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 28/08/13 |
| Director of Finance/CFO | 67 | 28/08/13 | |
Michael Halstead
PSD | President | 51 | 30/06/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 07/01/14 |
Joel Marcus
BRD | Director/Board Member | 76 | 28/08/13 |
| Director/Board Member | 67 | 07/01/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.14% | 16 M€ | -8.49% | ||
| 0.45% | 0 M€ | 0.00% | - | |
| 0.40% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 73.26 | +1.57% | 594,803 |
| 25/04/24 | 72.13 | -1.35% | 658,777 |
| 24/04/24 | 73.12 | -1.20% | 736,512 |
| 23/04/24 | 74.01 | -0.71% | 826,601 |
| 22/04/24 | 74.54 | +3.00% | 1,927,853 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Companyâs product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
73.26
USD
Average target price
90.28
USD
Spread / Average Target
+23.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.29% | 7.72B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- ITCI Stock
